Repare Therapeutics Inc.

NasdaqGS RPTX

Repare Therapeutics Inc. EPS (Diluted) for the year ending December 31, 2023: USD -2.23

Repare Therapeutics Inc. EPS (Diluted) is USD -2.23 for the year ending December 31, 2023, a -223.19% change year over year. EPS (Diluted) reflects the company's earnings per share adjusted for the potential dilution that could occur if all convertible securities were converted to common stock, providing a more conservative profitability measure.

Repare Therapeutics Inc. EPS (Diluted) for the year ending December 31, 2022 was USD -0.69, a 75.62% change year over year.
Repare Therapeutics Inc. EPS (Diluted) for the year ending December 31, 2021 was USD -2.83, a -95.17% change year over year.
Repare Therapeutics Inc. EPS (Diluted) for the year ending December 31, 2020 was USD -1.45, a -95.95% change year over year.
Repare Therapeutics Inc. EPS (Diluted) for the year ending December 31, 2019 was USD -0.74, a 17.78% change year over year.

Key data

Date	EPS (Diluted)	Shares (Diluted, Weighted)	Shares (Basic, Weighted)	Revenue

NasdaqGS: RPTX

Repare Therapeutics Inc.

CEO	Mr. Lloyd Mitchell Segal
IPO Date	June 19, 2020
Location	Canada
Headquarters	7210 Frederick-Banting
Employees	179
Sector	Healthcare
Industries Biotechnology Clinical Trials Pharmaceuticals

Description

Repare Therapeutics Inc., a clinical-stage precision oncology company, discovers and develops therapeutics by using its synthetic lethality approach in Canada and the United States. The company uses its SNIPRx, a proprietary, genome-wide, and CRISPR-enabled platform to systematically discover and develop highly targeted cancer therapies that focuses on genomic instability, including DNA damage repair. Its lead product candidate is RP-3500, an oral small molecule inhibitor for the treatment of solid tumors with specific DNA damage repair-related genomic alterations. It is also developing RP-6306, which is under Phase I clinical trial for tumors with genetic alterations characterized by CCNE1 amplification; and Polymerase Theta program, a SL target associated with BRCA mutations and other genomic alterations. The company was incorporated in 2016 and is headquartered in Montreal, Canada.

Key trends

Past 5 years